BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Caprotec Bioanalytics Appoints Dr. Jonathan Turner as Managing Director and Chief Executive Officer


10/19/2012 10:10:28 AM

BERLIN, Oct. 18, 2012 /PRNewswire/ --caprotec bioanalytics GmbH announced today a restructuring of its senior management and the appointment of Dr. Jonathan Turner as Managing Director and Chief Executive Officer. Dr. Turner joins caprotec as a highly regarded pharmaceutical executive and has held a number of senior management positions at global pharmaceutical companies, including Boehringer Ingelheim, AstraZeneca PLC and Schering AG.

Prof. Dr. Hubert Koester, Founder and previous Chief Executive Officer of caprotec, will continue to have a key role in the company, assuming responsibility for scientific strategy and technology development as Acting CSO and Chairman of the Scientific Advisory Board.

"Dr. Turner is a well-known and respected executive in the biotech industry.  He brings to caprotec a wealth of experience in management and in completing buy- and sell-side transactions between the pharmaceutical industry and biotech companies. His depth of knowledge in drug discovery is ideal to position caprotec's technology with key collaborative partners in the pharmaceutical and agrochemical industries," said Prof. Dr. Koester.

"Prof. Koesterhas demonstrated repeatedly his depth of vision and his ability to turn that into technologies of high commercial value. At caprotec he has nurtured another vision, now sufficiently validated to be transferred into the commercial arena. I look forward to being able to catalyze this step, and welcome that Prof. Koester will continue to support the company with his scientific expertise, drive, world-wide contacts, and the support of our broad-based investors," said Dr. Turner.

Prior to joining caprotec, Dr. Turner was Senior Vice President at XL Techgroup, a technology developer and equity firm connecting investors and biotech companies operating globally.  Prior to that, Dr. Turner held senior level management position in the pharmaceutical industry, including Corporate Head of Business Development and Licensing at Boehringer Ingelheim, Germany; Global Director of Respiratory and Inflammation Discovery Alliances at AstraZeneca PLC, UK; and Departmental Head of CNS Research at Schering AG, Berlin. He earned his doctoral degree in neuropharmacology at the University of St. Andrews, UK and lectured in psychiatry at the University of Newcastle, UK. He has been a member of several Supervisory Boards in the German biotech industry, has been responsible for two large international industry-academia consortia and has authored multiple peer reviewed publications.

About caprotec bioanalytics

caprotec bioanalytics is headquartered in Berlin, Germany and focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core feature consists of small, tri-functional molecules called Capture CompoundsTM which enable the identification of proteins that interact with drugs, or other small molecules, directly from complex biological samples. This world-leading platform is protected by a broad patent portfolio and has enormous potential in proteome analysis, drug development and the identification of biomarkers. This potential is being realized in collaborative partnerships within the global pharmaceutical and agrochemical industries. caprotec's current investors are Creathor Venture, Bad Homburg; IBB Beteiligungsgesellschaft mbH, Berlin; KfW Mittelstandsbank, Berlin; LBBW Venture Capital GmbH, Stuttgart and multiple private investors.

SOURCE caprotec bioanalytics


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->